# Medicinova Inc (MNOV)

Source: https://www.quantisnow.com/company/MNOV
Generated: 2026-11-11T16:14:06.733Z

- Ticker: MNOV
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001226616
- Website: medicinova.com

## About

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

## Latest MNOV news and filings

- 2026-10-12 10:00 UTC [MediciNova CEO Provides Shareholder Update](https://www.quantisnow.com/insight/medicinova-ceo-provides-shareholder-update-6743392)
- 2026-10-06 10:00 UTC [Conference Announcement] [MediciNova to Participate in the Maxim Growth Summit](https://www.quantisnow.com/insight/medicinova-to-participate-in-the-maxim-growth-summit-6737929)
- 2026-09-29 21:00 UTC [SEC Form 4] [Formerly 10% Owner 3d Investment Partners Pte. Ltd. sold $1,728,000 worth of shares (640,000 units at $2.70) (SEC Form 4)](https://www.quantisnow.com/insight/formerly-10-owner-3d-investment-partners-pte-ltd-sold-1728000-6729480)
- 2026-09-28 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-medicinova-inc-6727680)
- 2026-09-28 10:00 UTC [MediciNova Announces Topline Results from  MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)](https://www.quantisnow.com/insight/medicinova-announces-topline-results-from-mn-001-natg-202-clinical-trial-of-mn-001-6726900)
- 2026-09-24 10:00 UTC [MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)](https://www.quantisnow.com/insight/medicinova-announces-completion-of-last-patient-last-visit-in-the-6724645)
- 2026-09-17 12:41 UTC [Analyst Coverage Initiated] [Roth Capital initiated coverage on MediciNova with a new price target](https://www.quantisnow.com/insight/roth-capital-initiated-coverage-on-medicinova-with-a-new-price-6718591)
- 2026-09-08 10:00 UTC [Conference Announcement] [MediciNova to Participate in Two Investor Conferences in September](https://www.quantisnow.com/insight/medicinova-to-participate-in-two-investor-conferences-in-september-6707194)
- 2026-09-02 11:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-medicinova-inc-6702300)
- 2026-08-19 11:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-medicinova-inc-6687756)
- 2026-08-13 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-medicinova-inc-6680877)
- 2026-07-15 12:00 UTC [Conference Announcement] [MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients](https://www.quantisnow.com/insight/medicinova-announces-patient-enrollment-milestone-achieved-in-seanobi-study-expanded-access-program-6637628)
- 2026-06-30 12:00 UTC [MediciNova CEO Provides Shareholder Update](https://www.quantisnow.com/insight/medicinova-ceo-provides-shareholder-update-6619999)
- 2026-06-25 20:38 UTC [SEC Form 4] [SEC Form 4 filed by Director Nagao Hideki](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-nagao-hideki-6616092)
- 2026-06-25 20:35 UTC [SEC Form 4] [SEC Form 4 filed by Director Lemerond Nicole](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-lemerond-nicole-6616073)
- 2026-06-25 20:35 UTC [SEC Form 4] [SEC Form 4 filed by Director Beaver Carolyn](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-beaver-carolyn-6616072)
- 2026-06-24 20:38 UTC [SEC Form 8-K] [Medicinova Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/medicinova-inc-filed-sec-form-8-k-submission-of-matters-to-6614420)
- 2026-06-08 12:00 UTC [MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment](https://www.quantisnow.com/insight/medicinova-receives-notice-of-allowance-for-new-patent-covering-use-6592602)
- 2026-05-26 23:00 UTC [MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)](https://www.quantisnow.com/insight/medicinova-announces-completion-of-last-patient-last-visit-in-the-6573337)
- 2026-05-14 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-medicinova-inc-6554123)
- 2026-04-29 20:30 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-medicinova-inc-6521662)
- 2026-04-29 20:26 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-medicinova-inc-6521569)
- 2026-04-27 23:00 UTC [New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation](https://www.quantisnow.com/insight/new-peerreviewed-study-reveals-actionable-immunemicroenvironment-target-in-brain-metastasis-6517135)
- 2026-04-20 21:03 UTC [SEC Form PRER14A filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-prer14a-filed-by-medicinova-inc-6507023)
- 2026-04-17 20:57 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-medicinova-inc-6505221)
- 2026-03-16 12:42 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on MediciNova with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-medicinova-with-a-new-price-6448515)
- 2026-03-16 11:00 UTC [MediciNova to Participate at the 38th Annual ROTH Conference](https://www.quantisnow.com/insight/medicinova-to-participate-at-the-38th-annual-roth-conference-6448095)
- 2026-03-10 21:15 UTC [SEC Form 10-K] [SEC Form 10-K filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-medicinova-inc-6440310)
- 2026-02-20 11:25 UTC [SEC Form 8-K] [SEC Form 8-K filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-medicinova-inc-6403877)
- 2026-01-29 23:00 UTC [Conference Announcement] [MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients](https://www.quantisnow.com/insight/medicinova-announces-100-patients-enrolled-in-seanobi-study-expanded-access-program-eap-6366594)
- 2026-01-20 22:04 UTC [SEC Form 4] [SEC Form 4 filed by Chief Medical Officer Matsuda Kazuko](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-matsuda-kazuko-6354596)
- 2026-01-20 22:03 UTC [SEC Form 4] [SEC Form 4 filed by President and CEO Iwaki Yuichi](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-and-ceo-iwaki-yuichi-6354590)
- 2026-01-06 14:00 UTC [2026 New Year's Greetings from the CEO](https://www.quantisnow.com/insight/2026-new-years-greetings-from-the-ceo-6337573)
- 2025-12-30 12:55 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-medicinova-inc-6329397)
- 2025-12-30 12:53 UTC [SEC Form 8-K] [SEC Form 8-K filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-medicinova-inc-6329396)
- 2025-12-18 11:00 UTC [MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy](https://www.quantisnow.com/insight/medicinova-announces-completion-of-patient-enrollment-evaluating-mn-166-ibudilast-in-6321003)
- 2025-12-12 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-medicinova-inc-6313279)
- 2025-12-08 11:00 UTC [MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND](https://www.quantisnow.com/insight/medicinova-announces-update-and-basic-characteristic-randomized-patients-of-phase-6305933)
- 2025-12-05 21:23 UTC [SEC Form S-3] [SEC Form S-3 filed by Medicinova Inc](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-medicinova-inc-6305175)
- 2025-12-01 23:00 UTC [Message from the CEO to MediciNova Shareholders](https://www.quantisnow.com/insight/message-from-the-ceo-to-medicinova-shareholders-6298366)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MNOV
- Earnings history: https://www.quantisnow.com/earnings/MNOV
- Dividend history: https://www.quantisnow.com/dividends/MNOV
- Insider transactions: https://www.quantisnow.com/insiders/MNOV
- Options chain: https://www.quantisnow.com/options/MNOV
- SEC 8-K filings only: https://www.quantisnow.com/company/MNOV/8-k
- RSS and alerts for MNOV: https://www.quantisnow.com/docs/rss-feeds.md